Switch theme
Sign up to access all valuation multiples
InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.
2013
n/a
LTM Revenue $25.6M
LTM EBITDA -$34.9M
$2.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
InventisBio Co has a last 12-month revenue (LTM) of $25.6M and a last 12-month EBITDA of -$34.9M.
In the most recent fiscal year, InventisBio Co achieved revenue of $23.4M and an EBITDA of -$30.6M.
InventisBio Co expects next 12-month revenue of XXX and NTM EBITDA of XXX
See InventisBio Co valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $25.6M | XXX | $23.4M | XXX | XXX | XXX |
| Gross Profit | $25.0M | XXX | $22.9M | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | 98% | XXX | XXX | XXX |
| EBITDA | -$34.9M | XXX | -$30.6M | XXX | XXX | XXX |
| EBITDA Margin | -137% | XXX | -131% | XXX | XXX | XXX |
| EBIT | -$33.6M | XXX | -$36.6M | XXX | XXX | XXX |
| EBIT Margin | -131% | XXX | -156% | XXX | XXX | XXX |
| Net Profit | -$33.6M | XXX | -$33.3M | XXX | XXX | XXX |
| Net Margin | -131% | XXX | -142% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, InventisBio Co's stock price is CNY 31 (or $4).
InventisBio Co has current market cap of CNY 17.8B (or $2.5B), and EV of CNY 16.2B (or $2.2B).
See InventisBio Co trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.2B | $2.5B | XXX | XXX | XXX | XXX | $-0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, InventisBio Co has market cap of $2.5B and EV of $2.2B.
InventisBio Co's trades at 96.0x EV/Revenue multiple, and -73.4x EV/EBITDA.
Equity research analysts estimate InventisBio Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
InventisBio Co has a P/E ratio of -73.6x.
See valuation multiples for InventisBio Co and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV/Revenue | 88.0x | XXX | 96.0x | XXX | XXX | XXX |
| EV/EBITDA | -64.4x | XXX | -73.4x | XXX | XXX | XXX |
| EV/EBIT | -67.0x | XXX | -61.5x | XXX | XXX | XXX |
| EV/Gross Profit | 89.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -73.6x | XXX | -74.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -64.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInventisBio Co's last 12 month revenue growth is 39%
InventisBio Co's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
InventisBio Co's rule of 40 is -105% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
InventisBio Co's rule of X is -40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for InventisBio Co and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 39% | XXX | 39% | XXX | XXX | XXX |
| EBITDA Margin | -137% | XXX | -131% | XXX | XXX | XXX |
| EBITDA Growth | -11% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -105% | XXX | -92% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 228% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 254% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
InventisBio Co acquired XXX companies to date.
Last acquisition by InventisBio Co was XXXXXXXX, XXXXX XXXXX XXXXXX . InventisBio Co acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was InventisBio Co founded? | InventisBio Co was founded in 2013. |
| Where is InventisBio Co headquartered? | InventisBio Co is headquartered in China. |
| Is InventisBio Co publicy listed? | Yes, InventisBio Co is a public company listed on SHG. |
| What is the stock symbol of InventisBio Co? | InventisBio Co trades under 688382 ticker. |
| When did InventisBio Co go public? | InventisBio Co went public in 2022. |
| Who are competitors of InventisBio Co? | Similar companies to InventisBio Co include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of InventisBio Co? | InventisBio Co's current market cap is $2.5B |
| What is the current revenue of InventisBio Co? | InventisBio Co's last 12 months revenue is $25.6M. |
| What is the current revenue growth of InventisBio Co? | InventisBio Co revenue growth (NTM/LTM) is 39%. |
| What is the current EV/Revenue multiple of InventisBio Co? | Current revenue multiple of InventisBio Co is 88.0x. |
| Is InventisBio Co profitable? | Yes, InventisBio Co is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of InventisBio Co? | InventisBio Co's last 12 months EBITDA is -$34.9M. |
| What is InventisBio Co's EBITDA margin? | InventisBio Co's last 12 months EBITDA margin is -137%. |
| What is the current EV/EBITDA multiple of InventisBio Co? | Current EBITDA multiple of InventisBio Co is -64.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
